<DOC>
	<DOCNO>NCT01706510</DOCNO>
	<brief_summary>Assess pharmacodynamic effect ticagrelor vs. Clopidogrel American Indian patient stable coronary artery disease .</brief_summary>
	<brief_title>Antiplatelet Effects Ticagrelor Versus Clopidogrel American Indian Patients</brief_title>
	<detailed_description>A Single Center , Randomized , Open Label , Multiple Dose , Crossover Study Antiplatelet Effects Ticagrelor Versus Clopidogrel American Indian Patients With Stable Coronary Artery Disease</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
	<mesh_term>Purinergic P2 Receptor Antagonists</mesh_term>
	<criteria>Documented stable CAD fulfilling following , take 81mg ASA daily treatment : Females must post menopausal least one year surgically sterile least 6 month negative urine pregnancy test Selfidentified American Indian Genetic must sign informed consent genetic biological sample banking . Any indication oral anticoagulant dual antiplatelet treatment Concomitant therapy strong CYP3A inhibitor , CYP3A substrates narrow therapeutic index , strong CYP3A inducer within 14 day study treatment : Increased bleeding risk include : Diabetic patient HbAlC &gt; 10 % screen Contraindication clopidogrel , ASA , ticagrelor A history alcohol and/or substance abuse could interfere conduct trial Patients require dialysis Patients schedule revascularization ( e.g. , PCI , CABG ) study period Any acute chronic unstable condition past 30 day Known active recurrent hepatic disorder Patients ACS stent place within 12 month screen History Uric Acid nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Clopidogrel</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Purinergic P2Y Receptor Antagonists</keyword>
	<keyword>Purinergic P2 Receptor Antagonists</keyword>
	<keyword>Purinergic Antagonists</keyword>
	<keyword>Purinergic Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>